On this pageJump to a section
Picture the message your front desk gets on Tuesday morning: "Is it true there's a Wegovy pill now? Can I switch?"
That text is coming, if it has not already. On December 22, 2025, Novo Nordisk announced that the FDA had approved the Wegovy pill, a once-daily oral semaglutide that its release calls the first oral GLP-1 for weight loss in adults.1 For a telehealth clinic, the approval is a question about readiness, not a marketing opportunity to rush. This piece is about preparing your offers, your intake and your words. It contains no clinical claims, on purpose.
Educational content, not legal or medical advice. Talk to your counsel and medical director before you change anything patient-facing.
What did the FDA actually approve?
Start with the primary source and stay inside it.
According to Novo's release, the Wegovy pill is a 25 mg once-daily tablet, used with a reduced-calorie diet and increased physical activity in adults with obesity or with overweight and weight-related medical problems. The release also lists an indication to reduce the risk of major adverse cardiovascular events in certain adults with established cardiovascular disease.1 It highlights a Boxed Warning and a list of serious risks, and says the starting dose is expected in pharmacies and select telehealth providers in early January 2026.1
What I am not going to do
I am not going to summarize efficacy numbers, compare the pill with injections or tell anyone who should take it. Those belong in a conversation between a patient and a licensed prescriber, using the prescribing information. If you are tempted to paraphrase trial results in an ad, that is the signal to stop and bring in your counsel.
How does the pill change what patients ask for?
Mostly, it changes the questions that arrive before the consult.
Expect these new questions
- Is the pill available through your clinic, and when?
- Can I switch from what I take now, or start with the pill?
- What does it cost, with and without insurance?
- Is the pill the same as the compounded product I read about?
Notice that none of those have a marketing answer. The first and third are operational: a clinic either offers it or does not, and prices are public and shifting. The second and fourth are clinical or regulatory and go to a clinician.
Prepare a "what happens next" answer
Write one honest paragraph your team can send to every patient who asks. It might say that the pill is a prescription medication, that a licensed clinician decides what is appropriate for each person, and what the first step with you looks like. Keep it short and the same every time.
What happens to pricing when everyone can see the numbers?
Cash price is no longer a private conversation, as GLP-1 Prices Are Falling laid out last month.
| Public reference points | What a clinic should do |
|---|---|
| $499 per month for all Wegovy doses via NovoCare Pharmacy, March 2025 | Know where your offer sits against the manufacturer's own cash price |
| $350 cash price for Wegovy announced by the White House, November 2025 | Do not advertise a price you cannot back with current records |
| $150 for an oral GLP-1 starting dose, if approved, per the White House | Check the date on every figure you publish |
| $149 for the 1.5 mg pill starting dose, per Novo's release | Confirm before use, since offers can change |
The $499 cash price came from Novo's March 2025 NovoCare Pharmacy announcement.2 In November, the White House fact sheet described cash prices of $350 for Wegovy and, if approved, $150 for the initial dose of oral GLP-1s.3 Novo's approval release put the pill's starting dose at $149.1
Compete on service, not on a number
When the drug's price is public, your differentiation is the part you control: how fast someone is seen, how clear the process is, how well follow-up works. That is what a funnel can honestly promise. It cannot promise outcomes.
How should you adjust the funnel and intake?
Make small changes, and make each one deliberate.
- Add a plain-language page explaining what a consult involves, with no outcome claims and no price unless you can keep it current.
- Add a preference question to intake (see telehealth intake forms that convert without leaking PHI), such as whether the patient is interested in an oral or injectable option, and route the answer to the clinician. A preference is not a prescription.
- Update your FAQ and "last reviewed" dates on every page that mentions the pill.
- Write approved wording for the front desk, chat and DMs so everyone says the same thing.
- Pause or review any ad that uses brand names, then have your counsel read every revision. The Black Friday promotions checklist works for this too.
Keep products separate in your language
If your clinic offers more than one type of treatment, do not let the words blur. A patient reading a page should never be able to conclude that one product is the same as, or interchangeable with, another. This matters beyond the pill. In September 2025 the FDA announced a crackdown on deceptive drug advertising (my breakdown), with thousands of warning letters planned, roughly a hundred of them cease-and-desist letters, and citing "undisclosed paid influencer promotion" among its concerns.4
What should a clinic do in the next seven days?
Do less, in order.
First, get your medical director's decision on whether the clinic will offer the pill and from which date. Second, write the one-paragraph answer for patient questions. Third, review every live page and ad that mentions Wegovy and flag anything that implies equivalence or outcomes.
With any big product news, the clinics that handle it well are not the fastest to post. They are the ones whose intake, scripts and ads all say the same careful thing, because someone sat down and decided what they would say before the questions arrived. That is the funnel discipline I describe on my telehealth page.
Approval day is for being ready, not for being first.
This article is educational and is not legal advice. Talk to a qualified healthcare attorney about your situation.
Keep building.Ekai
Questions people ask
Did the FDA approve an oral Wegovy pill?
Yes. Novo Nordisk announced on December 22, 2025 that the FDA approved the Wegovy pill, a once-daily 25 mg oral semaglutide, described in its release as the first oral GLP-1 for weight loss in adults. Novo said it expected a full US launch in early January 2026.
How much will the Wegovy pill cost?
Novo's release listed $149 per month for the 1.5 mg starting dose through its savings offers, with coverage and savings details due at launch. Prices can change, so confirm the current figure before putting any number in an ad.
Can a telehealth clinic advertise the Wegovy pill?
Only a clinic that actually offers the approved product can describe it, and its claims should stay within the approved labeling. Do not describe any other product as the same as, or equivalent to, the pill. Check with your counsel and medical director.
Should marketing answer patients' medical questions about the pill?
No. Route questions about dosing, side effects, fit and alternatives to a licensed clinician. Marketing copy should help people book a consult, not substitute for one.
Sources
- 1
- 2
- 3
- 4
